{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T19:54:48Z","timestamp":1769802888264,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10067-025-07826-w","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:37:40Z","timestamp":1764275860000},"page":"1171-1179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of patients with major relapse in giant cell arteritis: a multicenter case\u2013control study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8997-6592","authenticated-orcid":false,"given":"Alice","family":"Rubinsztajn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Parreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Sailler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"de Boysson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Espitia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Hot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Perard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-2968","authenticated-orcid":false,"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4564-2931","authenticated-orcid":false,"given":"Sabine","family":"Mainbourg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"and the French Large Vessel Arteritis Study Group (GEFA)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"6","key":"7826_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/art.43098","volume":"77","author":"MA Alba","year":"2025","unstructured":"Alba MA, Unizony S, Warrington KJ, Murgia G, Prieto\u2010Gonz\u00e1lez S, Salvarani C, Matteson EL, Kermani TA (2025) Management of relapses in giant cell arteritis. Arthritis Rheumatol 77(6):632\u2013645. https:\/\/doi.org\/10.1002\/art.43098","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"7826_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/03009742.2021.1889025","volume":"51","author":"A Tomelleri","year":"2022","unstructured":"Tomelleri A, Campochiaro C, Sartorelli S, Farina N, Baldissera E, Dagna L (2022) Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study. Scand J Rheumatol 51(1):59\u201366. https:\/\/doi.org\/10.1080\/03009742.2021.1889025","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"7826_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/art.41165","volume":"72","author":"KB Gribbons","year":"2020","unstructured":"Gribbons KB, Ponte C, Craven A, Robson JC, Suppiah R, Luqmani R, Watts R, Merkel PA, Grayson PC (2020) Diagnostic assessment strategies and disease subsets in giant cell arteritis: data from an international observational cohort. Arthritis Rheumatol 72(4):667\u2013676. https:\/\/doi.org\/10.1002\/art.41165","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"7826_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/qjmed\/hcae105","volume":"117","author":"AF Gu\u00e9don","year":"2024","unstructured":"Gu\u00e9don AF, Froger C, Agard C, B\u00e9nichou A, Le Jeune S, Mekinian A, Morard M, Skaff Y, De Boysson H, Espitia O (2024) Identifying giant cell arteritis patients with higher risk of relapse and vascular events: a cluster analysis. QJM 117(11):769\u2013776. https:\/\/doi.org\/10.1093\/qjmed\/hcae105","journal-title":"QJM"},{"key":"7826_CR5","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s10067-024-07078-0","volume":"43","author":"A Agarwal","year":"2024","unstructured":"Agarwal A, Weisberg R, Mathew J et al (2024) Clinical features, imaging use, and management in giant cell arteritis: a retrospective single-center study. Clin Rheumatol 43:3409\u20133417. https:\/\/doi.org\/10.1007\/s10067-024-07078-0","journal-title":"Clin Rheumatol"},{"key":"7826_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrrheum.2012.97","volume":"8","author":"C Salvarani","year":"2012","unstructured":"Salvarani C, Pipitone N, Versari A, Hunder GG (2012) Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 8:509\u2013521. https:\/\/doi.org\/10.1038\/nrrheum.2012.97","journal-title":"Nat Rev Rheumatol"},{"key":"7826_CR7","doi-asserted-by":"publisher","first-page":"742","DOI":"10.55563\/clinexprheumatol\/xc46ld","volume":"43","author":"M\u00c1 Gonz\u00e1lez-Gay","year":"2025","unstructured":"Gonz\u00e1lez-Gay M\u00c1, Heras-Recuero E, Garc\u00eda-Fern\u00e1ndez A et al (2025) Revisiting the epidemiology of giant cell arteritis. Clin Exp Rheumatol 43:742\u2013748. https:\/\/doi.org\/10.55563\/clinexprheumatol\/xc46ld","journal-title":"Clin Exp Rheumatol"},{"key":"7826_CR8","doi-asserted-by":"publisher","unstructured":"Mackie SL, Yates M, Warrington KJ (2025) Polymyalgia rheumatica and giant cell arteritis: lumping versus splitting. Rheumatol Oxf Engl keaf589.  Epub ahead of print. https:\/\/doi.org\/10.1093\/rheumatology\/keaf589","DOI":"10.1093\/rheumatology\/keaf589"},{"key":"7826_CR9","doi-asserted-by":"publisher","unstructured":"Hellmich B, Agueda A, Monti S, et al (2019) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis.2020 Jan;79(1):19-30. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215672","DOI":"10.1136\/annrheumdis-2019-215672"},{"issue":"8","key":"7826_CR10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","volume":"73","author":"M Maz","year":"2021","unstructured":"Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, Archer A\u00a0M, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa\u2010Forte A, Turner AS, Mustafa RA (2021) 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol 73(8):1349\u20131365. https:\/\/doi.org\/10.1002\/art.41774","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"7826_CR11","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/acr.23901","volume":"72","author":"S Mainbourg","year":"2020","unstructured":"Mainbourg S, Addario A, Samson M, Pu\u00e9chal X, Fran\u00e7ois M, Durupt S, Gueyffier F, Cucherat M, Durieu I, Reynaud Q, Lega J-C (2020) Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta\u2010analysis. Arthritis Care Res 72(6):838\u2013849. https:\/\/doi.org\/10.1002\/acr.23901","journal-title":"Arthritis Care Res"},{"key":"7826_CR12","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1093\/rheumatology\/keaf237","volume":"64","author":"J Narv\u00e1ez","year":"2025","unstructured":"Narv\u00e1ez J, Dom\u00ednguez-\u00c1lvaro M, Hern\u00e1ndez-Rodr\u00edguez I et al (2025) Epidemiology of major and minor relapses in giant cell arteritis according to EULAR definitions: insights from the ARTESER registry. Rheumatology 64:4985\u20134994. https:\/\/doi.org\/10.1093\/rheumatology\/keaf237","journal-title":"Rheumatology"},{"key":"7826_CR13","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1097\/RHU.0000000000001942","volume":"29","author":"Q de Gomes Pinho","year":"2023","unstructured":"de Gomes Pinho Q, Daumas A, Benyamine A et al (2023) Predictors of relapses or recurrences in patients with giant cell arteritis: a medical records review study. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 29:e25\u2013e31. https:\/\/doi.org\/10.1097\/RHU.0000000000001942","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"4","key":"7826_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.semarthrit.2020.04.004","volume":"50","author":"F Muratore","year":"2020","unstructured":"Muratore F, Boiardi L, Restuccia G, Cavazza A, Catanoso M, Macchioni P, Spaggiari L, Cimino L, Aldigeri R, Pipitone N, Fontana A, Casali M, Croci S, Salvarani C (2020) Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: characteristics and predictors in a long-term follow-up study. Semin Arthritis Rheum 50(4):549\u2013558. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.004","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"7826_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102930","volume":"21","author":"M Aussedat","year":"2022","unstructured":"Aussedat M, Lobbes H, Samson M, Euvrard R, Lega J-C, Mainbourg S (2022) Epidemiology of major relapse in giant cell arteritis: a study-level meta-analysis. Autoimmun Rev 21(1):102930. https:\/\/doi.org\/10.1016\/j.autrev.2021.102930","journal-title":"Autoimmun Rev"},{"key":"7826_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00296-023-05527-8","volume":"44","author":"C Tsalapaki","year":"2024","unstructured":"Tsalapaki C, Lazarini A, Argyriou E et al (2024) Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis. Rheumatol Int 44:603\u2013610. https:\/\/doi.org\/10.1007\/s00296-023-05527-8","journal-title":"Rheumatol Int"},{"issue":"1","key":"7826_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105494","volume":"90","author":"L Moreel","year":"2023","unstructured":"Moreel L, Betrains A, Molenberghs G, Vanderschueren S, Blockmans D (2023) Epidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis. Joint Bone Spine 90(1):105494. https:\/\/doi.org\/10.1016\/j.jbspin.2022.105494","journal-title":"Joint Bone Spine"},{"key":"7826_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S et al (2017) Trial of tocilizumab in Giant-cell arteritis. N Engl J Med 377:317\u2013328. https:\/\/doi.org\/10.1056\/NEJMoa1613849","journal-title":"N Engl J Med"},{"key":"7826_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3899\/jrheum.181127","volume":"47","author":"A Dumont","year":"2020","unstructured":"Dumont A, Parienti J-J, Delmas C et al (2020) Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis. J Rheumatol 47:108\u2013116. https:\/\/doi.org\/10.3899\/jrheum.181127","journal-title":"J Rheumatol"},{"key":"7826_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/ard-2023-224543","volume":"83","author":"C Dejaco","year":"2024","unstructured":"Dejaco C, Ramiro S, Bond M et al (2024) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis 83:741\u2013751. https:\/\/doi.org\/10.1136\/ard-2023-224543","journal-title":"Ann Rheum Dis"},{"key":"7826_CR21","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.40520","volume":"70","author":"KSM van der Geest","year":"2018","unstructured":"van der Geest KSM, Sandovici M, van Sleen Y et al (2018) Review: what is the current evidence for disease subsets in giant cell arteritis? Arthritis Rheumatol 70:1366\u20131376. https:\/\/doi.org\/10.1002\/art.40520","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"7826_CR22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/rheumatology\/kew273","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B (2017) The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford, England) 56(4):506\u2013515. https:\/\/doi.org\/10.1093\/rheumatology\/kew273","journal-title":"Rheumatology (Oxford, England)"},{"issue":"3","key":"7826_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","volume":"54","author":"F Muratore","year":"2015","unstructured":"Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, Warrington KJ (2015) Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford, England) 54(3):463\u2013470. https:\/\/doi.org\/10.1093\/rheumatology\/keu329","journal-title":"Rheumatology (Oxford, England)"},{"key":"7826_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152814","volume":"74","author":"M Guarda","year":"2025","unstructured":"Guarda M, Hanson AC, Langenfeld HE, Crowson CS, Rakholiya J, Labarca C, Weyand CM, Warrington KJ, Koster MJ (2025) Concordance of relapse symptoms in patients with giant cell arteritis. Semin Arthritis Rheum 74:152814. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152814","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07826-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07826-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07826-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:01:56Z","timestamp":1769763716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07826-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7826"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07826-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics and Scientific Committee of the Hospices Civils de Lyon on June 1, 2023 (approval n\u00b022\u20135109). An information notice was provided to all participants in accordance with applicable regulations; written informed consent was therefore not required. All procedures involving human participants complied with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A related abstract was accepted as an e-poster presentation at the  91st National French Internal Medicine Society (SNFMI) Congress held in Tours from December 10 to 12, 2025.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Related congress abstract publication"}},{"value":"We declare no editing support. Artificial intelligence (ChatGPT, OpenAI) was used to improve the clarity and fluency of the English language in the manuscript. The authors reviewed and take full responsibility for the final content.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Editing support and AI use"}},{"value":"AR, SP, LP, SM, AH and JCL declare that they have no competing interests. LS has received personal fees or benefits from Abbvie, Novartis, Roche, and Chugai. HB reports receiving fees for serving on advisory boards from Roche-Chugai and Novartis and lecture fees from Roche-Chugai, Novartis, Fresenius Kabi, GlaxoSmithKline, Amicus therapeutics, and Sanofi. OE received fees for serving on advisory boards for Roche-Chugai and Novartis regarding biotherapy. PS has received institutional support from GSK and Novartis, and personal fees or benefits from Abbvie, GSK, Novartis, CHUGAI, UCB Pharma, Lilly, Fresenius Kabi, and Boehringer Ingelheim.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}